No Link Between CYP17 Gene and Breast Cancer Risk
Author Information
Author(s): AM Dunning, CS Healey, PDP Pharoah, NA Foster, JM Lipscombe, KL Redman, DF Easton, NE Day, BAJ Ponder
Primary Institution: CRC Human Cancer Genetics Research Group, Addenbrooke's Hospital, Cambridge
Hypothesis
Does the CYP17 gene polymorphism affect breast cancer risk in the English population?
Conclusion
The study found no significant association between the CYP17 gene polymorphism and breast cancer risk in the English population.
Supporting Evidence
- The study included a large sample size of 1426 participants.
- No significant differences in allele frequencies were found between cases and controls.
- The odds ratios for breast cancer risk associated with the C allele were not statistically significant.
Takeaway
The study looked at whether a specific gene change affects breast cancer risk, but it found that it doesn't seem to make a difference.
Methodology
A case-control study was conducted with 835 breast cancer cases and 591 control subjects, assessing the association between CYP17 polymorphism and breast cancer risk.
Limitations
The study population was predominantly white, which may limit the generalizability of the findings.
Participant Demographics
Women under 55 diagnosed with breast cancer in East Anglia, England.
Statistical Information
P-Value
0.35
Confidence Interval
0.89-1.37
Statistical Significance
p=0.35
Want to read the original?
Access the complete publication on the publisher's website